Nancy A. Niemuth
Battelle Memorial Institute
SerotypePathologyAntigenVirologyAntibodyChemistryImmunologyVaccinationAnthrax vaccinesEbola virusDiseaseBotulismAnthrax Vaccine AdsorbedSulfur mustardImmunoglobulin GToxicityClinical pathologyMedicineBiologyImmune systemPharmacology
37Publications
11H-index
439Citations
Publications 37
Newest
#1Milan T. TomicH-Index: 7
#2Shauna Farr-JonesH-Index: 14
Last. Doris M SnowH-Index: 2
view all 12 authors...
Source
#1Nancy A. Niemuth (Battelle Memorial Institute)H-Index: 11
#2Dawn Fallacara (Battelle Memorial Institute)H-Index: 2
Last. Yenny Goez-Gazi (Texas Biomedical Research Institute)H-Index: 5
view all 25 authors...
Filoviruses (Family Filoviridae genera Ebolavirus and Marburgvirus) are negative-stranded RNA viruses that cause severe health effects in humans and non-human primates, including death. Except in outbreak settings, vaccines and other medical countermeasures against Ebola virus (EBOV) will require testing under the FDA Animal Rule. Multiple vaccine candidates have been evaluated using cynomolgus monkeys (CM) exposed to EBOV Kikwit strain. To the best of our knowledge, however, animal model develo...
Source
#1Trevor BraselH-Index: 8
#2Jason E. ComerH-Index: 14
Last. Thomas L. RudgeH-Index: 11
view all 11 authors...
Recent studies have shown the domestic ferret (Mustela putorius furo) to be a promising small animal model for the study of Ebola virus (EBOV) disease and medical countermeasure evaluation. To date, most studies have focused on traditional challenge routes, predominantly intramuscular and intranasal administration. Here, we present results from a non-clinical pathogenicity study examining oronasal, oral, and ocular mucosal challenge routes in ferrets. Animals were challenged with 1, 10, or 100 p...
2 CitationsSource
#1Kendra J. Alfson (Texas Biomedical Research Institute)H-Index: 13
#2Yenny Goez-Gazi (Texas Biomedical Research Institute)H-Index: 5
Last. Patrick Keiser (Texas Biomedical Research Institute)H-Index: 1
view all 16 authors...
Ebola virus (EBOV) is a negative-sense RNA virus that can infect humans and nonhuman primates with severe health consequences. Development of countermeasures requires a thorough understanding of the interaction between host and pathogen, and the course of disease. The goal of this study was to further characterize EBOV disease in a uniformly lethal rhesus macaque model, in order to support development of a well-characterized model following rigorous quality standards. Rhesus macaques were intram...
#1Doris M SnowH-Index: 2
#2Ronald R. CobbH-Index: 7
Last. Milan T. TomicH-Index: 7
view all 13 authors...
Botulinum neurotoxins (BoNT) are extremely potent and can induce respiratory failure, requiring long-term intensive care to prevent death. Recombinant monoclonal antibodies (mAbs) hold considerable promise as BoNT therapeutics and prophylactics. In contrast, equine antitoxin cannot be used prophylactically and has a short half-life. Two three-mAb combinations are in development that specifically neutralize BoNT serotype A (BoNT/A) and B (BoNT/B). The three-mAb combinations addressing a single se...
2 CitationsSource
#1Nancy A. Niemuth (Battelle Memorial Institute)H-Index: 11
#2Thomas L. Rudge (Battelle Memorial Institute)H-Index: 11
Last. Carol L. K. Sabourin (Battelle Memorial Institute)H-Index: 24
view all 7 authors...
An anti-Zaire Ebola virus (EBOV) glycoprotein (GP) immunoglobulin G (IgG) enzyme linked immunosorbent assay (ELISA) was developed to quantify the serum levels of anti-EBOV IgG in human and non-human primate (NHP) serum following vaccination and/or exposure to EBOV. This method was validated for testing human serum samples as previously reported. However, for direct immunobridging comparability between humans and NHPs, additional testing was warranted. First, method feasibility experiments were p...
2 CitationsSource
#1Michael S. Anderson (Battelle Memorial Institute)H-Index: 5
#2Nancy A. Niemuth (Battelle Memorial Institute)H-Index: 11
Last. Thomas L. Rudge (Battelle Memorial Institute)H-Index: 11
view all 6 authors...
The need for an efficacious vaccine against highly pathogenic filoviruses was reinforced by the devastating 2014-2016 outbreak of Ebola virus (EBOV) disease (EVD) in Guinea, Sierra Leone, and Liberia that resulted in over 28,000 cases and over 11,300 deaths. In addition, the 2018-2020 outbreak in the Democratic Republic of the Congo currently has over 3,400 cases and over 2,200 deaths. A fully licensed vaccine and at least one other investigational vaccine are being deployed to combat this EVD o...
1 CitationsSource
#1Douglas BarkerH-Index: 10
#2Karen Gillum (Battelle Memorial Institute)H-Index: 2
Last. Shantha KodihalliH-Index: 6
view all 4 authors...
Botulism neurotoxins are highly toxic and are potential agents for bioterrorism. The development of effective therapy is essential to counter the possible use of these toxins in military and bioterrorism scenarios, and to provide treatment in cases of natural intoxication. Guinea pigs were intoxicated with a lethal dose of botulinum neurotoxin serotypes A, B, C, D, E, F or G, and at onset of the clinical disease intoxicated animals were treated with either BAT® [Botulism Antitoxin Heptavalent (A...
5 CitationsSource
#1Thomas L. Rudge (Battelle Memorial Institute)H-Index: 11
#2Karen A. Sankovich (Battelle Memorial Institute)H-Index: 1
Last. Carol L. K. Sabourin (Battelle Memorial Institute)H-Index: 24
view all 8 authors...
The need for an efficacious vaccine against highly pathogenic filoviruses was reinforced by the recent and devastating 2014–2016 outbreak of Ebola virus (EBOV) disease in Guinea, Sierra Leone, and Liberia that resulted in more than 10,000 casualties. Such a vaccine would need to be vetted through a U.S. Food and Drug Administration (FDA) traditional, accelerated, or Animal Rule or similar European Medicines Agency (EMA) regulatory pathway. Under the FDA Animal Rule, vaccine-induced immune respon...
10 CitationsSource
#1Milan T. TomicH-Index: 7
#2Yero EspinozaH-Index: 2
Last. James D. MarksH-Index: 89
view all 13 authors...
Botulinum neurotoxins (BoNT) are some of the most toxic proteins known, with a human LD50 of ~1 ng/kg. Equine antitoxin has a half-life in circulation of less than 1 day and is limited to a treatment rather than a prevention indication. The development of monoclonal antibodies (mAbs) may represent an alternative therapeutic option that can be produced at high quantities and of high quality and with half-lives of >10 days. Two different three mAb combinations are being developed that specifically...
12 CitationsSource